Literature DB >> 2386943

Androgen receptor gene expression in human prostate carcinoma cell lines.

W D Tilley1, C M Wilson, M Marcelli, M J McPhaul.   

Abstract

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heterogeneity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen receptor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP cell line contains high levels of both the androgen receptor protein and mRNA, the receptor-negative cell lines DU-145 and PC-3 do not express androgen receptor protein as detected by immunoblotting or mRNA as detected by Northern analysis or S1 nuclease protection. These results indicate that the absence of androgen receptor expression in the androgen receptor-negative cell lines is caused by diminished androgen receptor mRNA levels. Genomic Southern analysis indicates that the differences in androgen receptor expression in each of these cell lines is not associated with detectable alterations in the structure of the androgen receptor gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386943

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus.

Authors:  C D Wolfgang; M Essand; J J Vincent; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

3.  C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.

Authors:  A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

4.  LNCaP-OM, a new androgen-resistant prostate cancer subline.

Authors:  M Platica; R S Verma; M J Macera; O Platica
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

5.  Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines.

Authors:  J M Bentel; M A Pickering; M Pollard; J A Clements; W D Tilley
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

6.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.

Authors:  Y Umekita; R A Hiipakka; J M Kokontis; S Liao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines.

Authors:  F K Asadi; R Sharifi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

8.  Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.

Authors:  J Mad'arová; M Lukesová; A Hlobilková; M Strnad; B Vojtesek; R Lenobel; M Hajdúch; P G Murray; S Perera; Z Kolár
Journal:  Mol Pathol       Date:  2002-08

Review 9.  Androgen signal transduction and prostatic carcinoma.

Authors:  H Klocker; Z Culig; F Kaspar; A Hobisch; J Eberle; A Reissigl; G Bartsch
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

10.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.